Breast cancer: close surveillance for other solid tumors warranted

  • Yang H & al.
  • Breast Cancer Res
  • 16 Aug 2019

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with breast cancer are at risk of dying from breast cancer, but they also are at risk for death from other solid tumors, according to a nationwide Swedish prospective cohort.

Why this matters

  • Findings warrant stepped-up surveillance for other solid tumors.

Study design

  • Prospective nationwide cohort of 57,501 patients with breast cancer (2001-2011) from the Swedish Cancer Registry, matched by year of birth, county of residence, and socioeconomic status with 564,703 women from the general population.
  • Incidence and mortality were tracked, and P values were set at P<.00022 because of multiple comparisons.>
  • Funding: Swedish Research Council; others.

Key results

  • Median follow-up was 5.3 years in patients with breast cancer and 5.8 years for control participants.
  • Of 225 diseases under study, 45 among patients with breast cancer had HRs >1.5 and P<.00022.>
  • In terms of disease incidence, the highest HRs were for lymphedema, radiodermatitis, menopausal disorders, and neutropenia, all of which are adverse events related to surgery, radiotherapy, and chemotherapy.
  • In terms of mortality, the greatest risk was breast cancer (n=5405; HR not specified), followed by other solid tumors (n=890; HR, 1.16; 95% CI, 1.08-1.24). 
  • No other causes of death were significant.

Limitations

  • Observational design.
  • Some HRs not specified.